questionText: To ask the Secretary of State for Health and Social Care, what assessment has been made of the MHRA’s effectiveness at communicating known risks of sodium valproate, particularly in pregnancy, prior to 2018.
answerText: As with all medicines, the safety of valproate has been kept under continual review by the Medicines and Healthcare products Regulatory Agency (MHRA), ensuring the product information reflects what is known about valproate.The known risks of valproate are...
heading: Sodium Valproate: Health Education